Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

[-] Doc-Crentist | 5 points | Mar 04 2021 17:59:10

Interesting study to add to the debate- and disappointing.

I’m still curious to know what Andy Hill had found in his research and when/if Eli Schwartz will publish his data

[-] mekikichee | 5 points | Mar 04 2021 19:37:51

Yes, I agree, a little disappointing.

They found Ivermectin group (n=200) symptoms resolved in 10 days and symptoms in placebo (n=198) in 12 days.

However:

the relatively young and healthy study population rarely developed complications, rendering this study underpowered to detect such effects. Therefore, the ability of ivermectin to prevent the progression of mild COVID-19 to more severe stages would need to be assessed in larger trials.

A few things:

The effect was based solely on symptoms. No virological assessment were included. Objective data would have been nice to obtain while undertaking such a study.
Is Ivermectin in solution just as effective? Could there issues with potency/stability? Can someone with more knowledge chime in here?
conflict of interest disclosure should always be kept in mind 😬

[-] Doc-Crentist | 2 points | Mar 04 2021 19:48:25

That’s why I want E Schwartz to publish his findings- measured Virus load decreasing in ivm group vs placebo. I think it would pair well with another recent small study that measured inflammatory markers if I can remember right.

[-] Doc-Crentist | 2 points | Mar 04 2021 20:15:36

Doc Osgood has a pretty good scathing critique here: https://twitter.com/edoajoeric/status/1367566996380991497?s=21

[-] mekikichee | 1 points | Mar 04 2021 20:49:19

Lead pharmacist observed that a labeling error had occurred between Sept 29 and Oct 15, resulting in all patients receiving ivermectin and none receiving the placebo during this time frame.

This patient set was excluded and replaced.

If I understand his tweet properly, Dr. Osgood is suggesting this labeling error could have been present throughout the study and they should have checked plasma concentrations to confirm.

[-] open_reading_frame | 1 points | Mar 04 2021 21:56:18

Viral load is a surrogate endpoint and isn't validated to predict clinical benefit though. It would be nice to have but even if you have statistically better viral loads, you still need to prove that the difference is enough to be helpful.

[-] Doc-Crentist | 1 points | Mar 04 2021 22:09:41

https://youtu.be/h4y3xWCaPhw